2023-503659-88-00招募中3 期
J1I-MC-GZBM: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 389
- 试验地点
- 43
- 主要终点
- Percent Change from Baseline in Body Weight
研究概览
简要总结
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Have obesity.
- •Have established heart disease.
- •Have history of unsuccessful dietary weight loss effort
排除标准
- •have had the following within 90 days before screening: heart attack, stroke, a procedure to get blood flowing back into the heart, or been hospitalized for either congestive heart failure or sudden chest pain because of a blood clot in the heart
- •Have been taking weight loss drugs, including over-the-counter medications, within 90 days before screening
- •Have a self-reported change in body weight greater than 11 pounds within 90 days before screening.
- •have undergone weight loss surgery (e.g. stomach stapling, lap banding) within 1 year before screening
- •Have Type 1 diabetes
- •Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- •Have had chronic or acute pancreatitis
结局指标
主要结局
Percent Change from Baseline in Body Weight
Percent Change from Baseline in Body Weight
次要结局
未报告次要终点
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (43)
Loading locations...
相似试验
已完成
3 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseCardiovascular DiseasesObesityNCT05882045Eli Lilly and Company1,946
招募中
3 期
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1)Osteoarthritis, KneeObesity2023-503657-35-00Eli Lilly & Co.440
已完成
3 期
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeOverweightOsteo Arthritis KneeObesityNCT05931367Eli Lilly and Company445
进行中（未招募）
3 期
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityObesityNCT06662383Eli Lilly and Company800
进行中（未招募）
3 期
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainObesityNCT07035093Eli Lilly and Company586